grace targeted therapies lung cancer 2021 - new therapies: ntrk, ret and her2
Published 2 years ago • 70 plays • Length 22:44Download video MP4
Download video MP3
Similar videos
-
2:08
grace targeted therapies lung cancer 2021 - approved therapy for a cdkn2a secondary mutation?
-
4:42
grace targeted therapies in lung cancer 2021 - anxiety burden: wait for results, beginning treatment
-
17:58
grace targeted therapies lung cancer 2021 - kras directed therapies: a new horizon
-
2:56
grace targeted therapies lung cancer 2021 - what trials are available for ntrk resistant mutation?
-
6:18
grace targeted therapies lung cancer 2021 - will there ever be opportunity to use tki io together?
-
11:49
grace targeted therapies lung cancer 2021 - online communities, education & partnership in research
-
2:24
grace targeted therapies lung cancer 2021 - what makes mutations vary?
-
15:25
targeted therapies: the future of non-small cell lung cancer (nsclc) treatment?
-
14:33
grace targeted therapies lung cancer 2021 - targeted therapies in oligo-metastatic disease
-
2:34
grace targeted therapies lung cancer 2021 - recommended firstline treatment for kras k12c?
-
3:35
grace targeted therapies lung cancer 2021 - recommended treatment for an alk variant 1 patient
-
21:58
grace targeted therapies lung cancer 2021 - alk therapies-which one comes first, how do we sequence?
-
16:03
grace targeted therapies lung cancer 2021 -the role of chemotherapy in driver positive patients
-
3:09
grace targeted therapies lung cancer 2021 - best treatment patient with a designated kras mutation
-
17:53
grace targeted therapies lung cancer 2021 - genotype directed therapy: role in earlier stage disease
-
1:39
grace targeted therapies lung cancer 2021 - treatment after crizotinib in ros1 lung cancer
-
4:10
grace targeted therapies lung cancer 2021 - should patients with tumor removed get molecular testing
-
2:43
grace targeted therapies in lung cancer 2021 - opinions on various costs and treatment options
-
2:01
grace targeted therapies lung cancer 2021 - data learned from ensartinib for ros1 in clinical trial?